Cloud-Clone expands cardiovascular primary cell portfolio for translational research

Cloud-Clone says it has launched a traceable primary cardiovascular cell portfolio spanning more than 10 species and 50 subtypes, aimed at improving reproducibility in cardiovascular research and drug development. The release highlights source-level quality control, stocked inventory and specialized media as tools for researchers working from basic biology to translational medicine.

Why it matters: - Primary cardiovascular cells are widely used to model disease mechanisms, test drug candidates and bridge in-vivo and in-vitro research. - Cloud-Clone’s pitch addresses three long-running pain points in the field: inconsistent cell quality, limited species coverage and uneven identification standards. - The expanded portfolio is designed to support cardiovascular disease research, regenerative medicine, pre-clinical validation and veterinary drug development.

What happened: - Cloud-Clone said on Sept. 1, 2026, that it has built a full-chain quality-controlled primary cardiovascular cell portfolio. - The catalogue covers more than 10 species and over 50 cell subtypes. - The company says the portfolio is backed by self-operated SPF-grade animal facilities and an ISO-certified quality management system. - Cloud-Clone said the cells are intended for worldwide cardiovascular disease mechanism research and new drug development.

The details: - Cloud-Clone said its quality-control system covers source material, production workflow and final product release. - The company operates three SPF-grade barrier animal rooms totaling 1,000 m², with individually ventilated cage systems. - Strain introduction, breeding and tissue harvesting are handled in-house to reduce contamination risks. - Each batch undergoes morphological observation and tissue-specific immunofluorescence staining before release. - Cardiomyocytes are validated with ACTC1 antibody labeling. - Vascular endothelial cells are validated with FVIII or CD31 markers for von Willebrand factor expression. - Fibroblasts are characterized with fibronectin immunostaining. - Only batches with purity above 90% and viability above 85% are approved for shipment. - The portfolio includes primary cardiomyocytes and cardiac fibroblasts across eight species: rat, mouse, rabbit, dog, cat, pig, sheep and chicken. - The vascular lineup includes aortic endothelial cells, aortic smooth muscle cells, aortic adventitial fibroblasts, coronary artery endothelial cells and inferior vena cava smooth muscle cells. - The cardiac-supporting set includes cardiac valve interstitial cells, pericardial fibroblasts, endocardial and epicardial fibroblasts, and pericardial mesothelial cells. - The company said it keeps more than 560 primary-cell items in ready-to-ship inventory across multiple research fields. - Cardiovascular cell products are kept in stock for rapid delivery in major regions. - Cloud-Clone also offers custom serum-free or low-serum media, including the cardiomyocyte MSI007 series, matched to each cell type. - The company said the media are designed to preserve native phenotypes and differentiation functions while reducing stress from medium switching. - Researchers can find current inventory and technical resources on Cloud-Clone’s website. - Cloud-Clone also lists additional company information at its corporate website.

Between the lines: - The release is positioning primary cells as a premium alternative to less physiologically relevant models, especially where reproducibility and tissue specificity matter. - Broad species coverage is a commercial and scientific advantage because many cardiovascular studies still rely heavily on rodent models. - The emphasis on traceability, viability thresholds and batch validation suggests Cloud-Clone is targeting buyers who need documented quality for publication, screening and translational work.

What’s next: - Cloud-Clone said it will keep expanding species coverage and diversifying its primary-cell panels. - The company is also offering research support packages and technical consultation for global users. - Future use cases highlighted in the release include environmental exposure research, population-health risk assessment and early-warning studies using human coronary artery endothelial cells.

The bottom line: - Cloud-Clone is trying to make cardiovascular primary cells more standardized, more traceable and easier to deploy across research settings where reproducibility is a sticking point.